Literature DB >> 22857841

Pediatric urologic oncology.

Gwen M Grimsby1, Michael L Ritchey.   

Abstract

This article reviews common pediatric urologic cancers involving the genitourinary system. Rhabdomyosarcoma may occur in the bladder, prostate, paratesticular regions, vagina, or uterus. Some of these locations, such as the paratesticular region, have a more favorable outcome. Benign neoplasms account for the majority of pediatric testicular tumors and most are managed with testis-sparing surgery. Most genitourinary malignancies are expected to have a good outcome. One focus of treatment is organ preservation but not at the expense of a good oncologic outcome. Late sequelae of anticancer therapy are a concern and every attempt is made to decrease the intensity of tumor treatment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22857841     DOI: 10.1016/j.pcl.2012.05.018

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  3 in total

Review 1.  Pediatric genitourinary oncology.

Authors:  Francisco Tibor Dénes; Ricardo Jordão Duarte; Lílian Maria Cristófani; Roberto Iglesias Lopes
Journal:  Front Pediatr       Date:  2013-12-16       Impact factor: 3.418

2.  Mixed Botryoid and Spindle Cell Bladder Rhabdomyosarcoma: An Outstanding Pediatric Case.

Authors:  Tommaso Alterio; Roberto Chimenz; Salvatore Arena; Giovanni Conti; Sabrina Cardile; Carmelo Romeo; Carmelo Salpietro; Carmelo Fede
Journal:  Case Rep Pediatr       Date:  2017-01-01

3.  Dissecting Stages of Human Kidney Development and Tumorigenesis with Surface Markers Affords Simple Prospective Purification of Nephron Stem Cells.

Authors:  Naomi Pode-Shakked; Oren Pleniceanu; Rotem Gershon; Rachel Shukrun; Itamar Kanter; Efrat Bucris; Ben Pode-Shakked; Gal Tam; Hadar Tam; Revital Caspi; Sara Pri-Chen; Einav Vax; Guy Katz; Dorit Omer; Orit Harari-Steinberg; Tomer Kalisky; Benjamin Dekel
Journal:  Sci Rep       Date:  2016-03-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.